S-H.I. Ou

Natural History of Stage I Non-Small Cell Lung Cancer

Dan J. Raz, Jason A. Zell, S-H.I. Ou et al. · CHEST Journal · 2007 · 322 citations · Full text

Medicine, Natural History, Pathology +5

Progression-free survival (PFS) from a phase I study of crizotinib (PF-02341066) in patients with <i>ALK-</i>positive non-small cell lung cancer (NSCLC).

D. Ross Camidge, Yung‐Jue Bang, E.L. Kwak et al. · Journal of Clinical Oncology · 2011 · 135 citations

Progression-free Survival, Alk-positive Nsclc, Part 2 +14

Clinical activity of the oral ALK inhibitor PF-02341066 in ALK-positive patients with non-small cell lung cancer (NSCLC).

Y. Bang, E.L. Kwak, Alice T. Shaw et al. · Journal of Clinical Oncology · 2010 · 135 citations

Pharmacotherapy, Pre-clinical Pharmacology, Neuro-oncology +18

LBA6 KRYSTAL-1: Adagrasib (MRTX849) as monotherapy or combined with cetuximab (Cetux) in patients (Pts) with colorectal cancer (CRC) harboring a KRASG12C mutation

Rona Yaeger, Melissa L. Johnson, Alexander I. Spira et al. · Annals of Oncology · 2021 · 74 citations

Gastrointestinal Oncology, Lba6 Krystal-1, Medicine +10

Impact of crizotinib on survival in patients with advanced, ALK-positive NSCLC compared with historical controls.

Alice T. Shaw, B.Y. Yeap, Benjamin Solomon et al. · Journal of Clinical Oncology · 2011 · 38 citations

Prognostic Evaluation, Medicine, Alk-positive Nsclc +15